SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.

Altre lingue Shin Nippon Biomedical Laboratories, Ltd. Börse Stuttgart

Azioni

YB3

JP3379950003

Mercato chiuso - Börse Stuttgart Altri mercati azionari 08:15:54 07/06/2024			Variaz. 5gg	Var. 1 gen.
8,05 ^EUR	+1,26%		+3,25%	-25,00%

08/05	Shin Nippon Biomedical Laboratories, Ltd. fornisce previsioni di guadagno consolidate per i sei mesi che terminano il 30 settembre 2024 e l'anno che termina il 31 marzo 2025	CI
02/02	Shin Nippon Biomedical Laboratories, Ltd. Fornisce una guida agli utili consolidati per l'anno che terminerà il 31 marzo 2024	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Shin Nippon Biomedical Laboratories, Ltd. Announces Fiscal Year End Dividend for the Fiscal Year Ended March 31, 2024, Payable on June 25, 2024; Provides Second Quarter End and Fiscal Year End Dividend Guidance for the Fiscal Year Ended March 31, 2025	08/05
Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Forecasts for the Six Months Ending September 30, 2024 and Year Ending March 31, 2025	08/05
Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2024	02/02
Shin Nippon's STS101 Faces Regulatory Hurdle, FDA Requests Refinement for Approval	18/01
Shin Nippon Biomedical Laboratories : 英語版株主通信（2023/04/01~2023/09/30）を発行しました	27/12
Shin Nippon Biomedical Laboratories, Ltd. Announces Interim Dividend for the Year Ending March 31, 2024, Payable on November 30, 2023; Provides Dividend Guidance for the Year Ending March 31, 2024	07/11
Shin Nippon Biomedical Laboratories, Ltd. Provides Dividend Guidance for Second Quarter and Full Year Ending March 31, 2024	02/08/23
Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2023 and Full Year Ending March 31, 2024	02/08/23
Satsuma Pharmaceuticals and SNBL Announce Three Abstracts on STS101 for the Acute Treatment of Migraine to be presented at the American Headache Society's 65th Annual Scientific Meeting	16/06/23
Satsuma Pharmaceuticals and SNBL Announce Three Abstracts on STS101 for the Acute Treatment of Migraine to be Presented at the American Headache Society’s 65th Annual Scientific Meeting	15/06/23
Satsuma Pharmaceuticals and Shin Nippon Biomedical Laboratories, Ltd. Announce Three Abstracts on STS101 for the Acute Treatment of Migraine to Be Presented at the American Headache Society's 65th Annual Scientific Meeting	15/06/23
Shin Nippon Biomedical Laboratories, Ltd. completed the acquisition of the remaining 91.6% stake in Satsuma Pharmaceuticals, Inc. from a group of sellers.	08/06/23
Shin Nippon Biomedical Laboratories, Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023	08/05/23
Shin Nippon Biomedical Laboratories, Ltd. Provides Dividend Guidance for Second Quarter and Full Year Ending March 31, 2024	08/05/23
Shin Nippon Biomedical Laboratories, Ltd. Announces Year End Dividend for the Year Ended March 31, 2023, Payable on June 28, 2023	08/05/23
Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2023 and Full Year Ending March 31, 2024	08/05/23
Shin Nippon Biomedical to Make $30 Million Offer for US-based Satsuma Pharmaceuticals	18/04/23
Sector Update: Health Care Stocks Higher Premarket Monday	17/04/23
Bank Earnings in Focus as US Equity Futures Tread Water	17/04/23
Top Premarket Gainers	17/04/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Shin Nippon Biomedical Laboratories, Ltd. Börse Stuttgart

Azioni

YB3

JP3379950003

Altre lingue

Filtri